On November 23, 2021 KYAN Therapeutics Inc., a biotech company focused on improved cancer treatment outcomes, reported that data from clinical feasibility studies conducted by the National University of Singapore and Singapore’s National University Hospital will be presented at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting, to be held in Atlanta, Georgia and virtually on December 11-14, 2021 (Press release, KYAN Therapeutics, NOV 23, 2021, View Source [SID1234632305]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The studies demonstrated the clinical application of a personalized combination treatment platform for relapsed and refractory non-Hodgkin lymphoma patients. KYAN will be working with clinical collaborators in Singapore to conduct a Phase 2 clinical trial to evaluate this technology for personalized combination treatments in refractory T-cell lymphoma.
Details related to the oral presentations are as follows:
Title: Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study
Presenting Author: Sanjay De Mel, National University Cancer Institute Singapore
Abstract Number: 720
Session Name: 622. Lymphomas: Translational–Non-Genetic: Lymphoma biology Hematology Disease Topics & Pathways: Translational Research, Lymphomas, Diseases, Lymphoid Malignancies
Session Date: Monday, December 13, 2021
Session Time: 2:45 PM-4:15 PM
Presentation Time: 4:00 PM